Diogo O Souza Selected Research

Brain Ischemia (Cerebral Ischemia)

5/2021	Novel arylidene malonate derivative, KM-34, showed neuroprotective effects on in vitro and in vivo models of ischemia/reperfusion.
1/2019	JM-20 Treatment After MCAO Reduced Astrocyte Reactivity and Neuronal Death on Peri-infarct Regions of the Rat Brain.
8/2018	Multi-targeting effects of a new synthetic molecule (JM-20) in experimental models of cerebral ischemia.
2/2015	The effects of JM-20 on the glutamatergic system in synaptic vesicles, synaptosomes and neural cells cultured from rat brain.
10/2014	Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: mitoprotection against Ca²⁺-induced mitochondrial impairment.
10/2014	A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo.
10/2003	Diphenyl diselenide protects rat hippocampal slices submitted to oxygen-glucose deprivation and diminishes inducible nitric oxide synthase immunocontent.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diogo O Souza Research Topics

Disease

14	Alzheimer Disease (Alzheimer's Disease) 10/2023 - 04/2003
12	Seizures (Absence Seizure) 05/2022 - 08/2003
10	Pain (Aches) 01/2022 - 10/2008
9	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2023 - 11/2002
8	Ischemia 05/2021 - 06/2002
8	Schizophrenia (Dementia Praecox) 01/2015 - 10/2002
7	Brain Ischemia (Cerebral Ischemia) 05/2021 - 10/2003
7	Malnutrition (Nutritional Deficiencies) 07/2008 - 06/2002
6	Mania (Manias) 04/2011 - 12/2004
5	Neuroinflammatory Diseases 11/2023 - 11/2015
5	Dementia (Dementias) 01/2022 - 01/2003
5	Brain Diseases (Brain Disorder) 01/2021 - 10/2003
5	Brain Injuries (Brain Injury) 01/2016 - 09/2004
5	Body Weight (Weight, Body) 01/2015 - 04/2006
5	Bipolar Disorder (Manic Depressive Psychosis) 04/2011 - 12/2004
4	Memory Disorders (Memory Loss) 05/2022 - 01/2010
4	Chronic Pain 11/2021 - 02/2009
4	Hypoxia (Hypoxemia) 02/2016 - 04/2004
4	Epilepsy (Aura) 08/2011 - 01/2005
3	Hyperuricemia 01/2022 - 11/2021
3	Zika Virus Infection 01/2022 - 07/2019
3	Gout 01/2022 - 11/2021
3	Cognitive Dysfunction 01/2022 - 01/2007
3	Reperfusion Injury 05/2021 - 10/2014
3	Postoperative Cognitive Complications 11/2020 - 01/2016
3	Parkinson Disease (Parkinson's Disease) 07/2019 - 01/2005
3	Nervous System Diseases (Neurological Disorders) 01/2012 - 09/2002
3	Psychotic Disorders (Schizoaffective Disorder) 07/2005 - 11/2002
2	Pathologic Processes 01/2023 - 11/2020
2	Gliosis 11/2022 - 11/2015
2	Fibromyalgia (Fibrositis) 01/2022 - 11/2021
2	Ischemic Stroke 01/2021 - 07/2003
2	Stroke (Strokes) 01/2021 - 10/2014
2	Mitochondrial Diseases (Mitochondrial Disease) 11/2020 - 11/2010
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 07/2019 - 11/2013
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2019 - 01/2011
2	Infarction (Infarctions) 01/2019 - 10/2014
2	Amnesia (Dissociative Amnesia) 10/2011 - 01/2007
2	Acute Pain 04/2010 - 02/2009
2	Hyperalgesia 02/2010 - 02/2009

Drug/Important Bio-Agent (IBA)

23	Glutamic Acid (Glutamate)FDA Link 05/2021 - 08/2003
19	Proteins (Proteins, Gene)FDA Link 11/2023 - 06/2002
14	GuanosineIBA 01/2021 - 04/2004
11	PurinesIBA 01/2022 - 04/2004
11	Neuroprotective AgentsIBA 05/2021 - 06/2002
8	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2002
8	Adenosine (Adenocard)FDA LinkGeneric 01/2019 - 10/2002
8	GuanineIBA 02/2016 - 04/2004
7	Caffeine (No Doz)FDA LinkGeneric 01/2019 - 04/2003
7	Dizocilpine Maleate (Dizocilpine)IBA 02/2010 - 01/2003
7	Quinolinic AcidIBA 01/2008 - 08/2003
6	NucleosidesIBA 01/2021 - 09/2004
5	Allopurinol (Remid)FDA LinkGeneric 01/2022 - 01/2003
5	Amyloid beta-PeptidesIBA 01/2022 - 01/2004
5	Phosphopyruvate Hydratase (Enolase)IBA 11/2020 - 01/2005
5	N-Methylaspartate (NMDA)IBA 02/2009 - 01/2003
5	AcidsIBA 09/2007 - 06/2002
4	Amyloid (Amyloid Fibrils)IBA 11/2022 - 01/2013
4	EnzymesIBA 01/2022 - 12/2008
4	purineIBA 01/2022 - 01/2017
4	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 10/2003
4	AntioxidantsIBA 05/2018 - 07/2003
4	Adenine FDA LinkGeneric 02/2016 - 10/2008
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2015 - 03/2003
4	Amphetamine (Amfetamine)FDA LinkGeneric 07/2005 - 01/2003
4	ebselenIBA 11/2004 - 09/2002
3	Kainic Acid (Kainate)IBA 05/2022 - 06/2002
3	Xanthine OxidaseIBA 01/2022 - 11/2021
3	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2019 - 01/2012
3	Aspartic Acid (Aspartate)FDA Link 08/2018 - 02/2009
3	Inosine FDA Link 02/2016 - 09/2004
3	Oxygen (Dioxygen)IBA 11/2015 - 10/2003
3	Riluzole FDA LinkGeneric 11/2013 - 01/2003
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2013 - 01/2010
3	LithiumIBA 04/2011 - 06/2007
3	Anticonvulsants (Antiepileptic Drugs)IBA 02/2010 - 04/2004
3	Neurotransmitter Agents (Neurotransmitter)IBA 07/2008 - 11/2002
2	ApolipoproteinsIBA 10/2023 - 01/2023
2	Excitatory Amino Acid Transporter 2IBA 03/2023 - 01/2023
2	Messenger RNA (mRNA)IBA 01/2023 - 01/2020
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 05/2022 - 12/2013
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 05/2022 - 09/2003
2	Analgesics (Analgesic Drugs)IBA 01/2022 - 12/2021
2	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 01/2003
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2018 - 09/2004
2	1,4-dihydropyridine (dihydropyridine)IBA 02/2015 - 10/2014
2	Glutamate Receptors (Glutamate Receptor)IBA 02/2015 - 11/2004
2	Excitatory Amino AcidsIBA 10/2014 - 02/2009
2	Cytochromes c (Cytochrome c)IBA 10/2014 - 10/2014
2	Purinergic P1 Receptor AntagonistsIBA 01/2013 - 01/2007
2	Insulin (Novolin)FDA Link 01/2012 - 10/2011
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2011 - 01/2007
2	MercuryIBA 11/2010 - 10/2006
2	Uric Acid (Urate)IBA 08/2010 - 04/2010
2	Excitatory Amino Acid AgentsIBA 02/2010 - 12/2007
2	Adenosine Diphosphate (ADP)IBA 12/2008 - 09/2004
2	Antipsychotic Agents (Antipsychotics)IBA 08/2008 - 07/2005

Therapy/Procedure

7	Therapeutics 01/2023 - 06/2007
3	Oral Administration 01/2022 - 10/2014
2	Ligation 05/2015 - 02/2010